Teva targets India, China and Japan

The company raised its full-year revenue guidance to $16.4 billion.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) president and CEO Shlomo Yanai told “IDF Radio" (Galei Zahal), "The Indian and Chinese markets are on our screens for business. We've set up a new Asia division at Teva. We've begun with Japan, whose population is aging and which has a high standard of health and low level of generics. We're looking at India and China, but we're doing it in a calculated and measured way."

Teva raised its full-year revenue guidance for 2010 to $16.4 billion from $16 billion. The company kept is non-GAAP earnings per share guidance unchanged at $4.50-4.60.

Teva did not provide guidance for 2011.

Published by Globes [online], Israel business news - - on November 2, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018